Glucocerebrosides, particularly in the context of Gaucher's disease, are primarily studied for their role in medical and therapeutic applications. In Gaucher's disease, the accumulation of glucocerebrosides in cells, especially in the spleen, liver, and bone marrow, leads to various health complications. Enzyme replacement therapy (ERT) is a key application, where synthetic enzymes are administered to break down the excess glucocerebrosides, alleviating symptoms and improving patient quality of life. Additionally, substrate reduction therapy (SRT) is used to reduce the production of glucocerebrosides, offering an alternative treatment approach. Research into glucocerebrosides also extends to understanding their role in cellular metabolism and their potential as biomarkers for disease progression. These applications highlight the importance of glucocerebrosides in both clinical treatment and ongoing biomedical research.